Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 17, 2019

View Archived Issues

Anticoagulants prevent AD symptoms

P63 is behind thalidomide birth defects

Milasen, individualized gene therapy for rare genetic disease

Enterprise Therapeutics receives funding for development of novel CF therapy

Hepagene begins phase I trial of FXR agonist HPG-1860 for NASH

First patient enrolled in phase II study of novel cystic fibrosis treatment, BI-1265162

Further clinical data presented from phase I/II bladder cancer study of Alpha1H

Positive biomarker results presented from phase I study of XCUR-17

Preclinical evaluation of novel nonimmunogenic utrophin gene therapy for DMD

Bi-allelic loss of human APC2 is associated with recessive form of lissencephaly

New thioredoxin reductase 1 inhibitors identified at the University of Sharjah

Plexxikon discovers IDO-1 and TDO inhibitors

In vitro and in vivo characterization of [177Lu]DOTA-G-02113 and [68Ga]DOTA-G-02113 presented

Newly discovered protein modulates GABA, benzodiazepines

Relay Therapeutics and DE Shaw Research patent PTPN11 inhibitors

GC Pharma, Vaxess announce collaboration to develop release patch influenza vaccine

Shenzhen Targetrx Biotechnology discloses AXL/FLT3 inhibitors

New adamantane-containing compounds discovered at Hinova Pharmaceuticals

[68Ga]Ga-DO3A-S01-GCG: a first-in-class GCGR PET tracer with proof of concept in preclinical phase

UniQure enrolling patients with early manifest Huntington's disease for phase I/II study of AMT-130

New phase I study explores trivalent conjugate vaccine against invasive Salmonella disease

Nektar initiates first-in-human study of NKTR-255 in NHL and multiple myeloma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 26, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 27, 2026.
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Muted and missing M&As: JPM deals absent in 2026
BioWorld
For years, the J.P. Morgan Healthcare Conference (JPM) kicked off with splashy headlines of major M&A activity among biopharma companies, but in 2026, the hype...
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...